NEW YORK, April 30, 2025 ( GLOBE NEWSWIRE ) -- OTC Markets Group Inc. OTCM, operator of regulated markets for trading 12,000 U.S. and international securities, today announced Datatec Ltd DTCDTTLF DTTLY ) , an international ICT solutions and services group, has qualified to trade on the OTCQX® ...

WATERTOWN, Mass., April 30, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( NASDAQ: EYPT ) , a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call ...

VANCOUVER, BC, April 30, 2025 /PRNewswire/ -- Siyata Mobile Inc. SYTA SYTAW ) ) ( "Siyata" or the "Company" ) , a global developer and vendor of mission-critical Push-to-Talk over Cellular ( PoC ) handsets and accessories, is pleased to announce the release of the first shareholder Ask Me ...

Conference Call Scheduled for May 7, 2025, at 4:30 p.m. ET Conference Call Scheduled for May 7, 2025, at 4:30 p.m. ET ...

Urcosimod phase 2 trial treating Neuropathic Corneal Pain ( "NCP" ) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial. OKYO Pharma plans to analyze the efficacy data from the 17 patients who have now completed the Phase 2 trial.

Sanofi and CD&R close Opella transaction, create global consumer healthcare leader ...

ROCKVILLE, Md., April 30, 2025 ( GLOBE NEWSWIRE ) -- I-Mab IMAB ( the "Company" ) , a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abstract for a combination study of givastomig plus ...

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update • Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseases • Positive immunogenicity and good safety in interim results for wholly owned ...

Milestone order marks first commercial revenue for Sharps Technology under multi-year, 500-million syringe agreement Investments in best-in-class manufacturing equipment position Sharps to offer differentiated high-volume syringe production to meet long-term contract demand

BROOKFIELD, News, April 30, 2025 ( GLOBE NEWSWIRE ) -- Brookfield Infrastructure Partners L.P. ( Brookfield Infrastructure, BIP, or the Partnership ) ( NYSE: BIP. TSX: BIP.UN ) today announced its results for the first quarter ended March 31, 2025.